Clinical Scorecard: A Comprehensive Review and Meta-Analysis of Randomized Trials on Transurethral Resection of the Prostate Over Two Decades

At a Glance

Key Highlights

• TURP remains the gold standard surgical treatment for BPH despite emergence of minimally invasive therapies.
• Technological advancements over two decades have improved TURP outcomes, with better symptom scores and urine flow rates in recent years.
• Complication rates vary and are influenced by surgeon experience and patient factors such as anticoagulant use.

Guideline-Based Recommendations

Diagnosis

• Use International Prostate Symptom Score (IPSS), maximum urine flow rate (Qmax), and postvoid residual volume (PVR) to assess severity.
• Evaluate prostate-specific antigen (PSA) and prostate volume as part of preoperative assessment.
• Consider Sexual Health Inventory for Men (SHIM) to assess baseline sexual function.

Management

• TURP is recommended for patients with moderate to severe BPH symptoms refractory to medical therapy.
• Minimally invasive surgical therapies may be considered for patients at higher risk of complications or with smaller prostates.
• Avoid TURP in patients on blood thinners due to bleeding risk.

Monitoring & Follow-up

• Monitor perioperative complications including transurethral resection syndrome, bleeding, urinary retention, urinary tract infection, irritative symptoms, urinary incontinence, erectile dysfunction, retrograde ejaculation, urethral stricture, and bladder neck stenosis.
• Assess symptom improvement using IPSS and Qmax at 3 months, 1 year, and beyond 3 years postoperatively.
• Evaluate for incidental prostate cancer and need for retreatment at 1 and 3 years.

Risks

• Bleeding and need for blood transfusion are notable perioperative risks.
• Risk of urinary incontinence, erectile dysfunction, and retrograde ejaculation postoperatively.
• Potential for urethral stricture and bladder neck stenosis requiring further intervention.

Patient & Prescribing Data

Men with BPH undergoing TURP across various prostate sizes and symptom severities.

TURP provides significant and sustained improvement in IPSS (mean decrease ~16 points) and Qmax (mean increase ~12 ml/s) up to and beyond 3 years post-surgery, with better outcomes observed in more recent studies reflecting technological advances.

Clinical Best Practices

• Ensure surgeon experience and training to minimize complications and optimize outcomes.
• Select patients carefully, considering prostate size and anticoagulation status.
• Use standardized outcome measures (IPSS, Qmax, PVR) for consistent monitoring.
• Incorporate advances in endoscopic equipment and surgical techniques to improve efficacy and safety.
• Counsel patients regarding potential sexual side effects and risks of retreatment.

References

• PROSPERO Registration CRD42023401743
• PRISMA Guidelines